BioImpact Capital
Overview
BioImpact Capital is a biotechnology-focused venture capital firm based in Boston, Massachusetts. The firm specializes in developing and investing in companies that address pressing unmet medical needs, particularly in the fields of oncology and related areas. As an affiliate of MPM Capital, BioImpact Capital manages the UBS Oncology Impact Fund, focusing on investments in oncology and related fields. The firm's investment strategy encompasses various stages of company development, including early-stage, growth, late-stage, and pre-IPO investments. BioImpact Capital's portfolio spans multiple sectors within the biotechnology and healthcare industries, such as pharmaceuticals, medical devices, life sciences, oncology, therapeutics, cell and gene therapies, precision medicine, RNA medicines, medical technology, immunology, diagnostics, regenerative medicine, and biologics. With a team of approximately 50 professionals, BioImpact Capital manages over $2 billion in assets under management. The firm has a strong track record of supporting innovative companies and has been active in the field under the MPM brand for multiple decades. BioImpact Capital's commitment to delivering transformative therapies to patients is bolstered by its unparalleled entrepreneurial team with deep scientific expertise in developing, building, and investing in innovative biotechnology companies.
Investment Focus
- Companies addressing unmet medical needs
- Focus on oncology and related fields
- Innovative therapies with potential to transform patient outcomes
- Early-stage to pre-IPO companies
- Global presence in United States, Europe, and Asia
Portfolio Companies
Reach BioImpact Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about BioImpact Capital
What sectors does BioImpact Capital invest in?
BioImpact Capital invests in Healthcare, Life Sciences, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Boston, United States. BioImpact Capital is listed as a venture capital in the ConnectSafely investor database.
What stage does BioImpact Capital invest at?
BioImpact Capital backs companies at Early Stage, Growth, Late Stage and Pre-IPO, writing cheques of 5M - 50M.
Which regions does BioImpact Capital invest in?
BioImpact Capital invests across United States, Europe and Asia.
What companies has BioImpact Capital invested in?
BioImpact Capital's portfolio includes Aktis Oncology, Orna Therapeutics, Antiva Biosciences, ElevateBio and NextPoint Therapeutics.
How do I contact BioImpact Capital?
BioImpact Capital's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
